COIOSDeep risk insights through multi-disciplinary research across the globe
city buildings under blue sky during daytime
Item new Peer-reviewed Added

Aumolertinib with radiotherapy gave 34 months progression-free in EGFR-mutant lung cancer

In a trial stopped early, aumolertinib with radiotherapy gave median progression-free survival of 34.0 months against 7.4 months for chemotherapy with radiotherapy in EGFR-mutated stage III lung cancer.

The ADVANCE trial randomised 43 patients with unresectable EGFR-mutated stage III lung cancer to aumolertinib with radiotherapy or chemotherapy with radiotherapy, and stopped early. Median progression-free survival was 34.0 months in the aumolertinib arm against 7.4 months with chemotherapy and radiotherapy. In 125 patients outside the trial, a targeted drug with radiotherapy did as well with or without chemotherapy, both better than chemoradiotherapy alone.

Why it is interesting: Tests whether a targeted drug can replace chemotherapy alongside radiotherapy, with overall survival still immature at early stopping.

Source
Signal Transduction and Targeted Therapy, 21 September 2026
Paper
Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation
Authors
Bi N, Wang J, Jiang W, Fu X, Zhao L, Yang Z et al.
DOI
10.1038/s41392-026-02891-2
Type
Peer-reviewed article
Design
Open-label phase III randomised trial, 43 patients randomised of 98 planned, terminated at interim analysis, median follow-up 25.5 months, with a prespecified real-world cohort (n=125, median follow-up 32.7 months)
Verdict
New finding
Driver
Cancer
Driver
AI in medicine
Free full text
Free to read at the publisher

Other drivers in Health today